• Je něco špatně v tomto záznamu ?

Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes

Z. Šumnik, M. Pavlíková, V. Neuman, L. Petruželková, P. Konečná, P. Venháčová, J. Škvor, R. Pomahačová, D. Neumann, J. Vosáhlo, J. Strnadel, K. Kocourková, B. Obermannová, A. Šantová, L. Plachý, S. Průhová, O. Cinek, ČENDA Project Group

. 2024 ; 97 (1) : 70-79. [pub] 20230426

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007849

INTRODUCTION: The aim of the study was to assess the differences in key parameters of type 1 diabetes (T1D) control associated with treatment and monitoring modalities including newly introduced hybrid closed-loop (HCL) algorithm in children and adolescents with T1D (CwD) using the data from the population-wide pediatric diabetes registry ČENDA. METHODS: CwD younger than 19 years with T1D duration >1 year were included and divided according to the treatment modality and type of CGM used: multiple daily injection (MDI), insulin pump without (CSII) and with HCL function, intermittently scanned continuous glucose monitoring (isCGM), real-time CGM (rtCGM), and intermittent or no CGM (noCGM). HbA1c, times in glycemic ranges, and glucose risk index (GRI) were compared between the groups. RESULTS: Data of a total of 3,251 children (mean age 13.4 ± 3.8 years) were analyzed. 2,187 (67.3%) were treated with MDI, 1,064 (32.7%) with insulin pump, 585/1,064 (55%) with HCL. The HCL users achieved the highest median TIR 75.4% (IQR 6.3) and lowest GRI 29.1 (7.8), both p < 0.001 compared to other groups, followed by MDI rtCGM and CSII groups with TIR 68.8% (IQR 9.0) and 69.0% (7.5), GRI 38.8 (12.5) and 40.1 (8.5), respectively (nonsignificant to each other). These three groups did not significantly differ in their HbA1c medians (51.8 [IQR 4.5], 50.7 [4.5], and 52.7 [5.7] mmol/mol, respectively). NoCGM groups had the highest HbA1c and GRI and lowest TIR regardless of the treatment modality. CONCLUSION: This population-based study shows that the HCL technology is superior to other treatment modalities in CGM-derived parameters and should be considered as a treatment of choice in all CwD fulfilling the indication criteria.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007849
003      
CZ-PrNML
005      
20240423160329.0
007      
ta
008      
240412s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000530833 $2 doi
035    __
$a (PubMed)37100041
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šumnik, Zdenek $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
245    10
$a Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes / $c Z. Šumnik, M. Pavlíková, V. Neuman, L. Petruželková, P. Konečná, P. Venháčová, J. Škvor, R. Pomahačová, D. Neumann, J. Vosáhlo, J. Strnadel, K. Kocourková, B. Obermannová, A. Šantová, L. Plachý, S. Průhová, O. Cinek, ČENDA Project Group
520    9_
$a INTRODUCTION: The aim of the study was to assess the differences in key parameters of type 1 diabetes (T1D) control associated with treatment and monitoring modalities including newly introduced hybrid closed-loop (HCL) algorithm in children and adolescents with T1D (CwD) using the data from the population-wide pediatric diabetes registry ČENDA. METHODS: CwD younger than 19 years with T1D duration &gt;1 year were included and divided according to the treatment modality and type of CGM used: multiple daily injection (MDI), insulin pump without (CSII) and with HCL function, intermittently scanned continuous glucose monitoring (isCGM), real-time CGM (rtCGM), and intermittent or no CGM (noCGM). HbA1c, times in glycemic ranges, and glucose risk index (GRI) were compared between the groups. RESULTS: Data of a total of 3,251 children (mean age 13.4 ± 3.8 years) were analyzed. 2,187 (67.3%) were treated with MDI, 1,064 (32.7%) with insulin pump, 585/1,064 (55%) with HCL. The HCL users achieved the highest median TIR 75.4% (IQR 6.3) and lowest GRI 29.1 (7.8), both p &lt; 0.001 compared to other groups, followed by MDI rtCGM and CSII groups with TIR 68.8% (IQR 9.0) and 69.0% (7.5), GRI 38.8 (12.5) and 40.1 (8.5), respectively (nonsignificant to each other). These three groups did not significantly differ in their HbA1c medians (51.8 [IQR 4.5], 50.7 [4.5], and 52.7 [5.7] mmol/mol, respectively). NoCGM groups had the highest HbA1c and GRI and lowest TIR regardless of the treatment modality. CONCLUSION: This population-based study shows that the HCL technology is superior to other treatment modalities in CGM-derived parameters and should be considered as a treatment of choice in all CwD fulfilling the indication criteria.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    _2
$a mladiství $7 D000293
650    12
$a diabetes mellitus 1. typu $x farmakoterapie $7 D003922
650    _2
$a hypoglykemika $x terapeutické užití $7 D007004
650    _2
$a inzulin $x terapeutické užití $7 D007328
650    _2
$a glykovaný hemoglobin $7 D006442
650    _2
$a selfmonitoring glykemie $7 D015190
650    _2
$a krevní glukóza $7 D001786
650    _2
$a regulace glykemie $7 D000085002
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pavlíková, Marketa $u Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czechia
700    1_
$a Neuman, Vit $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Petruželková, Lenka $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Konečná, Petra $u Department of Pediatrics, University Hospital Brno, Brno, Czechia
700    1_
$a Venháčová, Petra $u Department of Pediatrics, University Hospital Olomouc, Olomouc, Czechia
700    1_
$a Škvor, Jaroslav $u Department of Pediatrics, Masaryk Hospital, Ústí nad Labem, Czechia
700    1_
$a Pomahačová, Renata $u Department of Pediatrics, University Hospital Pilsen, Pilsen, Czechia
700    1_
$a Neumann, David $u Department of Pediatrics, University Hospital Hradec Králové, Hradec Králové, Czechia
700    1_
$a Vosáhlo, Jan $u Department of Pediatrics, 3rd Faculty of Medicine, Prague, Czechia
700    1_
$a Strnadel, Jiri $u Department of Pediatrics, University Hospital Ostrava, Ostrava, Czechia
700    1_
$a Kocourková, Kamila $u Department of Pediatrics, Hospital České Budějovice, České Budějovice, Czechia
700    1_
$a Obermannová, Barbora $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Šantová, Alzbeta $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia $u 1st Faculty of Medicine, Prague, Czechia
700    1_
$a Plachý, Lukas $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Průhová, Stepanka $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
700    1_
$a Cinek, Ondrej $u Department of Pediatrics, Motol University Hospital and 2nd Faculty of Medicine, Prague, Czechia
710    2_
$a ČENDA Project Group
773    0_
$w MED00175757 $t Hormone research in paediatrics $x 1663-2826 $g Roč. 97, č. 1 (2024), s. 70-79
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37100041 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160325 $b ABA008
999    __
$a ok $b bmc $g 2081700 $s 1217616
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 97 $c 1 $d 70-79 $e 20230426 $i 1663-2826 $m Hormone research in paediatrics $n Horm Res Paediatr $x MED00175757
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace